FILSPARI holds strong market potential as the first FDA-approved non-immunosuppressive therapy for IgA nephropathy, a rare kidney disease with significant unmet needs. As more patients and providers ...

DelveInsight's "FILSPARI Market Size, Forecast, and Market Insight Report" highlights the details around FILSPARI, the first ...

CSL Vifor also includes the joint company Vifor Fresenius Medical Care Renal Pharma (with Fresenius Medical Care). At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical ...

If you buy through a BGR link, we may earn an affiliate commission, helping support our expert product labs. Getting addicted, no pun intended, to an animated conspiracy thriller from Adult Swim ...

The UK’s Competition and Markets Authority (CMA) has received a £23m ($29m) offer from Vifor Pharma for the NHS to address competition concerns that the regulator has been investigating.

What is Pharma 4.0? The term Industry 4.0 refers to the fourth industrial revolution, associated with the application of advanced technologies that have dramatically changed the landscape of ...

Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for ...

BRUSSELS, April 19 (Reuters) - Vifor Pharma has offered to launch a marketing campaign to address any damage caused by its criticisms of a rival to its key drug, EU regulators said on Friday ...

In this May 8, 2007, file photo, the Purdue Pharma logo is shown on the headquarters building in Stamford, Conn. Douglas Healey/AP, FILE In a statement, Purdue Pharma said: "We are confident in ...

The Delhi High Court said third parties who use different processes to make a patented product can’t be restricted if the plaintiff’s registration covers a product-by-process patent The Delhi High ...

However, CSL’s value growth has been driven by its immunoglobulin portfolio, the nearly $12 billion acquisition of Vifor Pharma and the launch of Hemgenix, its hemophilia B gene therapy with a $3.5 ...